-
Something wrong with this record ?
Estimating long-term health risks after breast cancer radiotherapy: merging evidence from low and high doses
C. Simonetto, D. Wollschläger, P. Kundrát, A. Ulanowski, J. Becker, N. Castelletti, D. Güthlin, E. Shemiakina, M. Eidemüller
Language English Country Germany
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2002-06-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-03-01 to 1 year ago
Health & Medicine (ProQuest)
from 2002-06-01 to 1 year ago
- MeSH
- Risk Assessment MeSH
- Smoking MeSH
- Leukemia MeSH
- Humans MeSH
- Lung Neoplasms MeSH
- Breast Neoplasms radiotherapy MeSH
- Heart Diseases MeSH
- Software MeSH
- Models, Theoretical * MeSH
- Dose-Response Relationship, Radiation MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
In breast cancer radiotherapy, substantial radiation exposure of organs other than the treated breast cannot be avoided, potentially inducing second primary cancer or heart disease. While distant organs and large parts of nearby ones receive doses in the mGy-Gy range, small parts of the heart, lung and bone marrow often receive doses as high as 50 Gy. Contemporary treatment planning allows for considerable flexibility in the distribution of this exposure. To optimise treatment with regards to long-term health risks, evidence-based risk estimates are required for the entire broad range of exposures. Here, we thus propose an approach that combines data from medical and epidemiological studies with different exposure conditions. Approximating cancer induction as a local process, we estimate organ cancer risks by integrating organ-specific dose-response relationships over the organ dose distributions. For highly exposed organ parts, specific high-dose risk models based on studies with medical exposure are applied. For organs or their parts receiving relatively low doses, established dose-response models based on radiation-epidemiological data are used. Joining the models in the intermediate dose range leads to a combined, in general non-linear, dose response supported by data over the whole relevant dose range. For heart diseases, a linear model consistent with high- and low-dose studies is presented. The resulting estimates of long-term health risks are largely compatible with rate ratios observed in randomised breast cancer radiotherapy trials. The risk models have been implemented in a software tool PASSOS that estimates long-term risks for individual breast cancer patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025272
- 003
- CZ-PrNML
- 005
- 20211026133954.0
- 007
- ta
- 008
- 211013s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00411-021-00924-8 $2 doi
- 035 __
- $a (PubMed)34275005
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Simonetto, Cristoforo $u Institute of Radiation Medicine, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany
- 245 10
- $a Estimating long-term health risks after breast cancer radiotherapy: merging evidence from low and high doses / $c C. Simonetto, D. Wollschläger, P. Kundrát, A. Ulanowski, J. Becker, N. Castelletti, D. Güthlin, E. Shemiakina, M. Eidemüller
- 520 9_
- $a In breast cancer radiotherapy, substantial radiation exposure of organs other than the treated breast cannot be avoided, potentially inducing second primary cancer or heart disease. While distant organs and large parts of nearby ones receive doses in the mGy-Gy range, small parts of the heart, lung and bone marrow often receive doses as high as 50 Gy. Contemporary treatment planning allows for considerable flexibility in the distribution of this exposure. To optimise treatment with regards to long-term health risks, evidence-based risk estimates are required for the entire broad range of exposures. Here, we thus propose an approach that combines data from medical and epidemiological studies with different exposure conditions. Approximating cancer induction as a local process, we estimate organ cancer risks by integrating organ-specific dose-response relationships over the organ dose distributions. For highly exposed organ parts, specific high-dose risk models based on studies with medical exposure are applied. For organs or their parts receiving relatively low doses, established dose-response models based on radiation-epidemiological data are used. Joining the models in the intermediate dose range leads to a combined, in general non-linear, dose response supported by data over the whole relevant dose range. For heart diseases, a linear model consistent with high- and low-dose studies is presented. The resulting estimates of long-term health risks are largely compatible with rate ratios observed in randomised breast cancer radiotherapy trials. The risk models have been implemented in a software tool PASSOS that estimates long-term risks for individual breast cancer patients.
- 650 _2
- $a nádory prsu $x radioterapie $7 D001943
- 650 _2
- $a vztah dávky záření a odpovědi $7 D004307
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a nemoci srdce $7 D006331
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leukemie $7 D007938
- 650 _2
- $a nádory plic $7 D008175
- 650 12
- $a teoretické modely $7 D008962
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a kouření $7 D012907
- 650 _2
- $a software $7 D012984
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Wollschläger, Daniel $u Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Obere Zahlbacher Str. 69, 55131, Mainz, Germany
- 700 1_
- $a Kundrát, Pavel $u Institute of Radiation Medicine, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany $u Department of Radiation Dosimetry, Nuclear Physics Institute of the Czech Academy of Sciences, Na Truhlářce 39/64, 180 00, Prague 8, Czech Republic
- 700 1_
- $a Ulanowski, Alexander $u Institute of Radiation Medicine, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany $u IAEA Environment Laboratories, International Atomic Energy Agency, 2444, Seibersdorf, Austria
- 700 1_
- $a Becker, Janine $u Institute of Radiation Medicine, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany
- 700 1_
- $a Castelletti, Noemi $u Institute of Radiation Medicine, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany $u Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, 80802, Munich, Germany
- 700 1_
- $a Güthlin, Denise $u Institute of Radiation Medicine, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany $u Department of Radiation Protection and Health, Federal Office for Radiation Protection, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany
- 700 1_
- $a Shemiakina, Elena $u Institute of Radiation Medicine, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany
- 700 1_
- $a Eidemüller, Markus $u Institute of Radiation Medicine, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany. markus.eidemueller@helmholtz-muenchen.de
- 773 0_
- $w MED00004025 $t Radiation and environmental biophysics $x 1432-2099 $g Roč. 60, č. 3 (2021), s. 459-474
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34275005 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026134000 $b ABA008
- 999 __
- $a ok $b bmc $g 1714360 $s 1145779
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 60 $c 3 $d 459-474 $e 20210717 $i 1432-2099 $m Radiation and environmental biophysics $n Radiat Environ Biophys $x MED00004025
- LZP __
- $a Pubmed-20211013